论文部分内容阅读
目的 了解多发性骨髓瘤(MM)患者骨髓单个核细胞(BMMNC)及骨髓瘤细胞系(KM3细胞)中4种TRAIL受体的表达情况,探讨TRAIL的选择性杀瘤机制及化疗药物对TRAIL受体的影响。方法 应用半定量RT PCR和流式细胞术检测23例MM患者、15名正常对照者BMMNC和KM3细胞中4种TRAIL受体的表达,并比较了12例MM患者化疗前后BMMNC及KM3细胞与阿霉素共孵育前后4种TRAIL受体表达的变化。结果 MM患者BMMNC死亡受体DR4、DR5的表达均高于正常对照组(P<0. 05),DR5的表达高于DR4(P<0. 05);诱捕受体DcR1、DcR2在MM组中的表达明显低于正常对照组(P<0. 05);KM3细胞死亡受体DR4、DR5强表达,未检测到诱捕受体DcR1、DcR2的表达; MM患者化疗后BMMNC及KM3细胞与阿霉素共孵育后DR5的表达均上调(P<0. 05)。结论 死亡受体DR4、DR5和诱捕受体DcR1、DcR2在MM患者BMMNC和正常人BMMNC中表达有差异,这可能是TRAIL可以选择性杀死MM细胞而对正常细胞无毒性作用的机制之一; MM患者化疗后BMMNC及KM3细胞与阿霉素共孵育后死亡受体DR5表达上调,提示化疗药物可能通过上调死亡受体DR5的表达而促使细胞凋亡。
Objective To investigate the expression of four TRAIL receptors in bone marrow mononuclear cells (BMMNC) and myeloma cell line (KM3) in patients with multiple myeloma (MM) and to explore the mechanism of selective tumorigenicity of TRAIL and the effect of chemotherapeutic agents on TRAIL receptor The impact of the body. Methods The expression of four TRAIL receptors in BMMNC and KM3 cells from 23 patients with MM and 15 normal controls were detected by semi-quantitative RT-PCR and flow cytometry. The BMMNC and KM3 cells in 12 patients with MM were compared with that of KM3 cells Changes of four kinds of TRAIL receptor expression before and after co - incubation with. Results The expression of DR4 and DR5 in BMMNC patients was higher than that in normal controls (P <0.05), and the expression of DR5 was higher in DR patients than that in DR4 (P <0.05). The expression of DcR1 and DcR2 (P <0.05). The expressions of DcR1 and DcR2 were not detected in DR4 and DR5 of KM3 cells. The expression of DcR1 and DcR2 was not detected in BMMNC and KM3 cells in MM patients after chemotherapy After co-incubation with DR5, the expression of DR5 was up-regulated (P <0.05). Conclusions The expression of DR4, DR5 and trapping receptors DcR1 and DcR2 are different between BMMNC and normal BMMNC patients, which may be one of the mechanisms by which TRAIL selectively kill MM cells without toxic effects on normal cells. After chemotherapy, BMMNC and KM3 cells co-incubated with doxorubicin in MM patients, the death receptor DR5 expression increased, suggesting that chemotherapy drugs may promote apoptosis by up-regulating the expression of death receptor DR5.